A 65-year-old woman’s progressive neurological deterioration led clinicians to an unexpected diagnosis: paraneoplastic neurologic syndrome secondary to small cell lung cancer. This case, recently published in the Canadian Medical Association Journal, underscores a critical diagnostic reality that often goes unrecognized in clinical practice.
Paraneoplastic neurologic syndromes occur when the immune system targets both tumor cells and neural tissue, resulting in neurological symptoms that can precede cancer detection by months or even years. In up to 80% of cases, patients present with neurological complaints before any malignancy is identified, making early recognition essential for timely intervention.
The case highlights why clinicians evaluating progressive neurological symptoms should maintain a high index of suspicion for underlying malignancy. Prompt antibody testing and cancer screening can expedite diagnosis and improve treatment outcomes for patients experiencing these complex syndromes.
Read the full article on GMJ Newsroom.
Was this article helpful?
